DigiPath, Euphoria partner to set highest medical marijuana patient safety and education standards

DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc. (OTCBB and OTCQB: DIGPD), has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary. Euphoria Wellness, expected to be the first cannabis dispensary to open in Las Vegas, chose to partner with DigiPath Labs as part of its strategy to set the highest medical marijuana patient safety and education standards in the industry.

"DigiPath Labs will analyze samples of products sold by Euphoria Wellness for unsafe levels of contaminants such as heavy metals, microbes, mycotoxins, pesticides, and solvents, which can exacerbate patient health issues," says Todd Denkin, president of DigiPath Labs. "We will also quantify cannabinoid and terpenoid levels and deliver detailed reports that Euphoria's staff can use to help patients."

Comprehensive cannabis potency testing is critical for patient care. Cannabis is believed to contain over 400 medicinal compounds, most notably cannabinoids and terpenoids, each of which affects the body differently. One compound, THC, is known to induce cancerous cell death. Another compound, CBD, keeps certain cancers from spreading. Different compounds can reduce tissue inflammation, treat epilepsy, and fight methicillin-resistant Staphylococcus aureus (MRSA) infections.

The amount (potency) of each compound present in cannabis medicines can vary widely. Potency is affected by plant genetics, growing conditions, curing and extraction methods, and other factors. Quantifying cannabinoids and terpenoids present in a product is critical to predicting its biological effect on patients.

"Detailed cannabinoid and terpenoid potency reports from DigiPath Labs will enable Euphoria Wellness employees to recommend specific products to patients," says Darlene Purdy, Managing Director at Euphoria Wellness. "We will also educate patients, so that they are able to choose products based on the medicinal properties listed in DigiPath Labs' reports in the future."

Source:

DigiPath, Inc.

Advertisement

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Research sheds light on composition of cannabis used to treat children with epilepsy